JP2021525541A - 変異体Ｃｐｆ１エンドヌクレアーゼ - Google Patents

変異体Ｃｐｆ１エンドヌクレアーゼ Download PDF

Info

Publication number
JP2021525541A
JP2021525541A JP2020567958A JP2020567958A JP2021525541A JP 2021525541 A JP2021525541 A JP 2021525541A JP 2020567958 A JP2020567958 A JP 2020567958A JP 2020567958 A JP2020567958 A JP 2020567958A JP 2021525541 A JP2021525541 A JP 2021525541A
Authority
JP
Japan
Prior art keywords
seq
cpf1
nucleic acid
target nucleic
ortholog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525541A5 (https=
Inventor
ステラ，ステファノ
モントヤ，ギエルモ
Original Assignee
ユニバーシティ オブ コペンハーゲン
ユニバーシティ オブ コペンハーゲン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ コペンハーゲン, ユニバーシティ オブ コペンハーゲン filed Critical ユニバーシティ オブ コペンハーゲン
Publication of JP2021525541A publication Critical patent/JP2021525541A/ja
Publication of JP2021525541A5 publication Critical patent/JP2021525541A5/ja
Priority to JP2024226441A priority Critical patent/JP2025075025A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020567958A 2018-06-04 2019-06-04 変異体Ｃｐｆ１エンドヌクレアーゼ Pending JP2021525541A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024226441A JP2025075025A (ja) 2018-06-04 2024-12-23 変異体Ｃｐｆ１エンドヌクレアーゼ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18175707 2018-06-04
EP18175707.1 2018-06-04
EP18190950.8 2018-08-27
EP18190950 2018-08-27
PCT/EP2019/064444 WO2019233990A1 (en) 2018-06-04 2019-06-04 Mutant cpf1 endonucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024226441A Division JP2025075025A (ja) 2018-06-04 2024-12-23 変異体Ｃｐｆ１エンドヌクレアーゼ

Publications (2)

Publication Number Publication Date
JP2021525541A true JP2021525541A (ja) 2021-09-27
JP2021525541A5 JP2021525541A5 (https=) 2022-07-05

Family

ID=66676556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567958A Pending JP2021525541A (ja) 2018-06-04 2019-06-04 変異体Ｃｐｆ１エンドヌクレアーゼ
JP2024226441A Pending JP2025075025A (ja) 2018-06-04 2024-12-23 変異体Ｃｐｆ１エンドヌクレアーゼ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024226441A Pending JP2025075025A (ja) 2018-06-04 2024-12-23 変異体Ｃｐｆ１エンドヌクレアーゼ

Country Status (12)

Country Link
US (2) US12152257B2 (https=)
EP (1) EP3802806A1 (https=)
JP (2) JP2021525541A (https=)
KR (1) KR20210028163A (https=)
CN (1) CN112424349A (https=)
AU (1) AU2019282094A1 (https=)
BR (1) BR112020024736A2 (https=)
CA (1) CA3102676A1 (https=)
IL (1) IL279153A (https=)
MA (1) MA52739A (https=)
MX (1) MX2020013229A (https=)
WO (1) WO2019233990A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
CN111521781B (zh) * 2020-02-24 2021-07-30 广州医科大学附属第一医院（广州呼吸中心） 一种用于新冠肺炎病毒SARS-CoV-2核酸的检测试剂盒及其检测方法
JP7850156B2 (ja) * 2020-12-17 2026-04-22 モンサント テクノロジー エルエルシー 操作されたｓｓＤＮａｓｅ不含ＣＲＩＳＰＲエンドヌクレアーゼ
EP4284923A1 (en) 2021-01-29 2023-12-06 Wageningen Universiteit Crispr-associated base-editing of the complementary strand
US20250025572A1 (en) * 2021-11-29 2025-01-23 Editas Medicine, Inc. Engineered crispr/cas12a effector proteins, and uses thereof
WO2023166030A1 (en) 2022-03-01 2023-09-07 BASF Agricultural Solutions Seed US LLC Cas12a nickases
JP2025511267A (ja) 2022-03-30 2025-04-15 ビーエーエスエフ アグリカルチュラル ソリューションズ シード ユーエス エルエルシー 最適化塩基エディター
AU2023380182A1 (en) 2022-11-18 2025-07-03 Kyoto Prefectural Public University Corporation Compositions for mitophagy induction and uses thereof
WO2024133272A1 (en) 2022-12-21 2024-06-27 BASF Agricultural Solutions Seed US LLC Increased editing efficiency by co-delivery of rnp with nucleic acid
US20250001010A1 (en) 2023-06-30 2025-01-02 Christiana Care Gene Editing Institute, Inc. Nras gene knockout for treatment of cancer
US20250319206A1 (en) 2024-04-04 2025-10-16 Christina Care Gene Editing Institute, Inc. Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2
WO2025226816A1 (en) 2024-04-23 2025-10-30 Christiana Care Gene Editing Institute, Inc. Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes
CN119506249B (zh) * 2024-11-29 2025-11-07 大连理工大学 一种多PAM选择的基因编辑系统NovaCas-1及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009511A2 (en) * 2015-06-18 2016-04-20 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017064546A1 (en) * 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
WO2017106657A1 (en) * 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
CN106244591A (zh) * 2016-08-23 2016-12-21 苏州吉玛基因股份有限公司 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用
CN109790527A (zh) 2016-07-26 2019-05-21 通用医疗公司 普氏菌属和弗朗西斯氏菌属的CRISPR1(Cpf1)的变体
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
SG10201913505WA (en) 2016-10-17 2020-02-27 Univ Nanyang Tech Truncated crispr-cas proteins for dna targeting
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018195540A1 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Inducible, tunable, and multiplex human gene regulation using crispr-cpf1
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
WO2018209014A1 (en) 2017-05-10 2018-11-15 Regents Of The University Of Minnesota Programmable transcription factors and methods
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11866697B2 (en) 2017-05-18 2024-01-09 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
KR102655021B1 (ko) 2017-07-11 2024-04-04 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11649442B2 (en) 2017-09-08 2023-05-16 The Regents Of The University Of California RNA-guided endonuclease fusion polypeptides and methods of use thereof
WO2019075197A1 (en) 2017-10-11 2019-04-18 The General Hospital Corporation METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
US20210079366A1 (en) 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US11884947B2 (en) 2018-02-23 2024-01-30 Shanghaitech University Fusion proteins for base editing
KR102287880B1 (ko) 2018-03-26 2021-08-09 고쿠리츠다이가쿠호진 고베다이가쿠 세포에서 이중 가닥 dna의 표적 부위를 변형시키기 위한 방법
KR102922694B1 (ko) 2018-04-19 2026-02-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 유전자 편집을 위한 조성물 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009511A2 (en) * 2015-06-18 2016-04-20 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017064546A1 (en) * 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
WO2017106657A1 (en) * 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof

Also Published As

Publication number Publication date
CA3102676A1 (en) 2019-12-12
US12152257B2 (en) 2024-11-26
CN112424349A (zh) 2021-02-26
EP3802806A1 (en) 2021-04-14
BR112020024736A2 (pt) 2021-03-23
JP2025075025A (ja) 2025-05-14
US20210230567A1 (en) 2021-07-29
IL279153A (en) 2021-01-31
MA52739A (fr) 2021-04-21
US20250163394A1 (en) 2025-05-22
WO2019233990A1 (en) 2019-12-12
KR20210028163A (ko) 2021-03-11
MX2020013229A (es) 2021-04-28
AU2019282094A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP2021525541A (ja) 変異体Ｃｐｆ１エンドヌクレアーゼ
JP7605852B2 (ja) クラスｉｉのｖ型ｃｒｉｓｐｒ系
EP3814527B1 (en) Crispr effector system based amplification methods, systems, and diagnostics
WO2023114090A2 (en) Signal boost cascade assay
US20210207203A1 (en) Crispr double nickase based amplification compositions, systems, and methods
US20240169179A2 (en) Novel class 2 type ii and type v crispr-cas rna-guided endonucleases
US20240271129A1 (en) Rna-guided cas nucleases and uses thereof in diagnostics and therapy
EP3768855B1 (en) Methods and compositions for recombinase-mediated selective cleavage of nucleic acids
CA3219005A1 (en) Mutant cas12j endonucleases
CN116179511A (zh) Cpf1蛋白在制备用于核酸检测的试剂盒中的应用
US20110104762A1 (en) Detection probe acting by molecular recognition
Kuzuya et al. DNA, PNA, and their derivatives for precise genotyping of SNPs
CN118599832A (zh) CRISPR/Cas12a系统直接靶向目标RNA基因并激活核酸酶侧切活性的方法
HK40042172B (en) Crispr effector system based amplification methods, systems, and diagnostics
MX2007003497A (es) Ensayo genómico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122